InAADR

Drug Information

Drug Name: Clofibrate (637-07-0)
PubChem ID: 2796
SMILES: CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl
InchiKey: KNHUKKLJHYUCFP-UHFFFAOYSA-N
Therapeutic Category:

Computed Drug Properties

Molecular Weight (dalton): 242.702
LogP: 3.0605
Ring Count: 1
Hydrogen Bond Acceptor Count: 3
Hydrogen Bond Donor Count: 0
Total Polar Surface Area: 35.53

This panel provides information on interacting drugs and their ADRs along with references

Interacting drug Toxicity Interaction Type Mechanism Reference

This panel provides drug-protein interaction and their ADRs along with references

Toxicity Interacting Protein Mechanism Reference
Hyperplasia Carnitine O-acetyltransferase (P43155) Clofibrate induced the activities of carnitine acetyltransferase (90-fold) and NADP-linked malic enzyme (3-fold) to the same level in periportal as in perivenous hepatocytes@associate with marked liver enlargement and hyperplasia. [ ADR Type 2 ] Clofibrate induces carnitine acyltransferases in periportal and perivenous zones of rat liver and does not disturb the acinar zonation of gluconeogenesis
Hyperplasia NADP-linked malic enzyme (Q3LR75) Clofibrate induced the activities of NADP-linked malic enzyme (3-fold)@associate with marked liver enlargement and hyperplasia [ ADR Type 2 ] Clofibrate induces carnitine acyltransferases in periportal and perivenous zones of rat liver and does not disturb the acinar zonation of gluconeogenesis
Liver Enlargement Hyperplasia Carnitine O-palmitoyltransferase (P50416) Clofibrate induced the activities of carnitine palmitoyltransferase (3-fold)@associate with marked liver enlargement and hyperplasia [ ADR Type 2 ] Clofibrate induces carnitine acyltransferases in periportal and perivenous zones of rat liver and does not disturb the acinar zonation of gluconeogenesis

This panel provides drug-food interactions and their ADRs along with references

Food Toxicity Reference

This panel provides information on metabolites and their ADRs along with references

Metabolite Toxicity Place of Metabolism Mechanism Reference

This panel provides information on drug category

Toxicity Source
Acute Kidney Injury MetaADEDB
Adenoma Liver Cell MetaADEDB
Arrhythmias Cardiac MetaADEDB
Back Pain MetaADEDB
Blood Coagulation Disorders MetaADEDB
Carcinoma Hepatocellular MetaADEDB
Cardiomyopathies MetaADEDB
Cell Transformation Neoplastic MetaADEDB
Chest Pain MetaADEDB
Cholelithiasis MetaADEDB
Coronary Disease MetaADEDB
Dermatofibrosarcoma MetaADEDB
Diabetes Insipidus MetaADEDB
Disseminated Intravascular Coagulation MetaADEDB
Drug-Induced Liver Injury MetaADEDB
Dyslipidemias MetaADEDB
Dyspnea MetaADEDB
Edema MetaADEDB
Embolism Fat MetaADEDB
Erectile Dysfunction MetaADEDB
Exanthema MetaADEDB
Fatty Liver MetaADEDB
Gallstones MetaADEDB
Granuloma MetaADEDB
Heart Diseases MetaADEDB
Hemorrhage MetaADEDB
Hepatomegaly MetaADEDB
Hypercholesterolemia MetaADEDB
Hyperlipidemias MetaADEDB
Hyperlipoproteinemias MetaADEDB
Hyperoxaluria MetaADEDB
Hyperplasia MetaADEDB
Hypertension MetaADEDB
Hypertriglyceridemia MetaADEDB
Hypertrophy MetaADEDB
Leiomyoma MetaADEDB
Liver Diseases MetaADEDB
Liver Neoplasms Experimental MetaADEDB
Mitochondrial Myopathies MetaADEDB
Muscle Weakness MetaADEDB
Muscular Atrophy MetaADEDB
Muscular Diseases MetaADEDB
Myocardial Infarction MetaADEDB
Myoglobinuria MetaADEDB
Nausea MetaADEDB
Necrosis MetaADEDB
Nephritis Interstitial MetaADEDB
Neurologic Manifestations MetaADEDB
Neuromuscular Diseases MetaADEDB
Neuromuscular Manifestations MetaADEDB
Niemann-Pick Disease Type C MetaADEDB
Pain MetaADEDB
Pancreatic Neoplasms MetaADEDB
Polyuria MetaADEDB
Precancerous Conditions MetaADEDB
Pulmonary Edema MetaADEDB
Substance Withdrawal Syndrome MetaADEDB
Uremia MetaADEDB
Urinary Bladder Neoplasms MetaADEDB
Vomiting MetaADEDB

InAADR: Drug-Protein-ADRs database